Inspection Record

Sincerus Florida, LLC — FDA 483 Findings

US FDAInspected 2026-05-29Published 2026-07-22 7 findingsQuality unit oversightEquipment and facilityContamination controlProcess validationAseptic processing and sterility assurance

Inspectors Annet R. RajanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release.

2Equipment and facility

Written procedures are not established and followed for the cleaning and maintenance of equipment, including, utensils, used in the manufacture.

3Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing or fully followed.

4Contamination control

Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established, written or followed.

5Process validation

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

6Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

7Equipment and facility

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

About this record

Extracted automatically from the document US FDA published on 2026-07-22. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Sincerus Florida, LLC company profile — full history US FDA documents, 2026 Go to Findings search